Difference between type 1 and type 2 diabetes
Reading File
Searching Images
type 1 vs type 2 diabetes comparison diagram
Finding Sources
Searching Images
diabetes mellitus type 1 autoimmune beta cell destruction pathophysiology
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Here is a detailed comparison:
Type 1 vs. Type 2 Diabetes Mellitus
Overview
| Feature | Type 1 Diabetes (T1D) | Type 2 Diabetes (T2D) |
|---|---|---|
| Frequency | 5-10% of all diabetes | ~90-95% of all diabetes |
| Age of onset | Any age; most common in children and young adults | Middle age or older; increasingly seen in obese children/adolescents |
| Insulin dependency | Always required | Variable - may not be needed initially |
| Autoimmunity | Present (autoimmune disease) | Absent |
| C-peptide | Very low or undetectable | Detectable (measurable) |
| Body habitus | Usually lean | Often overweight or obese |
Pathogenesis
Type 1 Diabetes
T1D is an autoimmune disease in which immune effector cells (primarily T cells) attack and destroy pancreatic beta cells. The destruction typically begins years before clinical symptoms appear, and symptoms only manifest after >90% of beta cells have been destroyed.
Key mechanisms:
- Genetic susceptibility: Over 20 susceptibility loci are known. The strongest association is with HLA class II genes (HLA-DR3 and/or DR4 are present in 90-95% of European-descent patients with T1D). Polymorphisms in the insulin gene, CTLA4, and PTPN22 also increase risk.
- Autoimmune attack: Self-tolerance to beta-cell antigens fails. T cells infiltrate the islets (called "insulitis") and destroy beta cells via type IV hypersensitivity.
- Autoantibodies: Anti-insulin (IAA), anti-GAD65, anti-IA-2, and anti-ZnT8 antibodies are detectable years before clinical disease, serving as biomarkers.
- Environmental triggers: Viral infections (e.g., coxsackievirus), changes in the microbiome, and other environmental factors are implicated but not fully understood.
The result is absolute insulin deficiency - the pancreas produces little to no insulin.
(Robbins & Kumar Basic Pathology, p. 745)
Type 2 Diabetes
T2D results from two concurrent defects:
- Peripheral insulin resistance - Skeletal muscle, adipose tissue, and liver respond poorly to insulin, requiring higher insulin levels to maintain glucose homeostasis.
- Relative insulin deficiency - Beta cells initially compensate by secreting more insulin, but over time progressive beta-cell dysfunction and reduction in beta-cell mass means they can no longer keep up.
There is no autoimmunity. The underlying genetic defects for most T2D cases are not fully determined; it is polygenic in most cases.
(Goldman-Cecil Medicine; Robbins & Kumar Basic Pathology)
Risk Factors
| Type 1 | Type 2 |
|---|---|
| Genetic (HLA-DR3/DR4) | Genetic (polygenic, strong family history) |
| Autoimmune predisposition | Obesity (BMI ≥25, or ≥23 in Asian Americans) |
| Environmental triggers (viral infections) | Sedentary lifestyle |
| - | Advanced age (≥45 years) |
| - | High-risk ethnicity (African American, Latino, Asian American, Native American, Pacific Islander) |
| - | Hypertension, dyslipidemia |
| - | Polycystic ovary syndrome (PCOS) |
| - | History of gestational diabetes |
Clinical Presentation
Type 1: Onset can be abrupt. Patients are usually symptomatic at diagnosis - presenting with the classic triad: polyuria, polydipsia, and polyphagia, often with weight loss. In the first 1-2 years after onset, residual beta cells may still produce some insulin (a "honeymoon period"), but eventually exogenous insulin becomes essential.
Type 2: Onset is often insidious. Many patients are asymptomatic and diagnosed incidentally on routine blood tests. It is not uncommon to discover T2D only after complications have already developed.
Acute Complications
| Complication | Type 1 | Type 2 |
|---|---|---|
| Diabetic ketoacidosis (DKA) | Common and severe | Rare (can occur under extreme stress) |
| Hyperosmolar hyperglycemic state (HHS) | Uncommon | Can occur |
| Hypoglycemia | Common (from insulin therapy) | Risk increases if on insulin/sulfonylureas |
DKA is the hallmark acute emergency of T1D. The absolute insulin deficiency causes unrestrained lipolysis, excessive ketone production (from free fatty acid oxidation), and metabolic acidosis. Blood glucose typically reaches 500-700 mg/dL. - Robbins & Kumar Basic Pathology
Treatment
| Type 1 | Type 2 |
|---|---|
| Insulin is mandatory (multiple daily injections or insulin pump) | Lifestyle modification first (diet, exercise, weight loss) |
| No oral agents sufficient alone | Oral agents: metformin (first-line), sulfonylureas, SGLT-2 inhibitors, GLP-1 agonists, etc. |
| No proven prevention | Metformin or acarbose can delay/prevent onset in high-risk individuals |
| - | Insulin commonly added as disease progresses |
Associated Conditions
- Type 1: Other autoimmune diseases - particularly thyroid disease (Hashimoto's thyroiditis, Graves' disease), celiac disease, Addison's disease.
- Type 2: Metabolic syndrome components - obesity, hypertension, dyslipidemia, PCOS. Strong association with cardiovascular disease.
Key Diagnostic Markers
| Test | Type 1 | Type 2 |
|---|---|---|
| Autoantibodies (GAD65, IA-2, IAA, ZnT8) | Positive (in most) | Negative |
| C-peptide | Very low or absent | Present (may decline over years) |
| HbA1c | Elevated | Elevated |
| Fasting glucose | Elevated | Elevated |
Sources:
- Henry's Clinical Diagnosis and Management by Laboratory Methods - comparison table of T1D vs T2D characteristics
- Goldman-Cecil Medicine International Edition - definitions and pathogenesis, p. 573-588
- Robbins & Kumar Basic Pathology - detailed pathogenesis of T1D and T2D, p. 745+
This is a shared conversation. Sign in to Orris to start your own chat.